Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1393 to 1398 of 1398 entries
Sorted by: Best Match Show Resources per page
A critical assessment of the medication-related osteonecrosis of the jaw classification in stage I patients: a retrospective analysis.

Journal of the Korean Association of Oral and Maxillofacial Surgeons

Ristow O, Hürtgen L, Moratin J, Smielowski M, Freudlsperger C, Engel M, Hoffmann J, Rückschloß T.
PMID: 33911042
J Korean Assoc Oral Maxillofac Surg. 2021 Apr 30;47(2):99-111. doi: 10.5125/jkaoms.2021.47.2.99.

OBJECTIVES: It is unclear whether the extent of intraoral mucosa defects in patients with medication-related osteonecrosis of the jaw indicates disease severity. Therefore, this study investigated whether mucosal lesions correlate with the true extent of osseous defects in stage...

Cite
Ristow O, Hürtgen L, Moratin J, et al. A critical assessment of the medication-related osteonecrosis of the jaw classification in stage I patients: a retrospective analysis. J Korean Assoc Oral Maxillofac Surg. 2021;47(2):99-111doi: 10.5125/jkaoms.2021.47.2.99.
Ristow, O., Hürtgen, L., Moratin, J., Smielowski, M., Freudlsperger, C., Engel, M., Hoffmann, J., & Rückschloß, T. (2021). A critical assessment of the medication-related osteonecrosis of the jaw classification in stage I patients: a retrospective analysis. Journal of the Korean Association of Oral and Maxillofacial Surgeons, 47(2), 99-111. https://doi.org/10.5125/jkaoms.2021.47.2.99
Ristow, Oliver, et al. "A critical assessment of the medication-related osteonecrosis of the jaw classification in stage I patients: a retrospective analysis." Journal of the Korean Association of Oral and Maxillofacial Surgeons vol. 47,2 (2021): 99-111. doi: https://doi.org/10.5125/jkaoms.2021.47.2.99
Ristow O, Hürtgen L, Moratin J, Smielowski M, Freudlsperger C, Engel M, Hoffmann J, Rückschloß T. A critical assessment of the medication-related osteonecrosis of the jaw classification in stage I patients: a retrospective analysis. J Korean Assoc Oral Maxillofac Surg. 2021 Apr 30;47(2):99-111. doi: 10.5125/jkaoms.2021.47.2.99. PMID: 33911042; PMCID: PMC8084747.
Copy Download .nbib Format: NLM
Promoting adolescent health through integrated human papillomavirus vaccination programs: The experience of Togo.

Vaccine

Engel D, Afeli ADJ, Morgan C, Zeck W, Ross DA, Vyankandondera J, Bloem P, Adjeoda KR.
PMID: 34844819
Vaccine. 2021 Nov 26; doi: 10.1016/j.vaccine.2021.11.021. Epub 2021 Nov 26.

The introduction of the Human papillomavirus (HPV) vaccine has shown potential to not only prevent cervical cancer but also drive adolescents' access to other health care services, even in low-income countries. Few studies have been conducted to date to...

Cite
Engel D, Afeli ADJ, Morgan C, et al. Promoting adolescent health through integrated human papillomavirus vaccination programs: The experience of Togo. Vaccine. 2021;doi: 10.1016/j.vaccine.2021.11.021.
Engel, D., Afeli, A. D. J., Morgan, C., Zeck, W., Ross, D. A., Vyankandondera, J., Bloem, P., & Adjeoda, K. R. (2021). Promoting adolescent health through integrated human papillomavirus vaccination programs: The experience of Togo. Vaccine, . https://doi.org/10.1016/j.vaccine.2021.11.021
Engel, Danielle, et al. "Promoting adolescent health through integrated human papillomavirus vaccination programs: The experience of Togo." Vaccine vol. (2021). doi: https://doi.org/10.1016/j.vaccine.2021.11.021
Engel D, Afeli ADJ, Morgan C, Zeck W, Ross DA, Vyankandondera J, Bloem P, Adjeoda KR. Promoting adolescent health through integrated human papillomavirus vaccination programs: The experience of Togo. Vaccine. 2021 Nov 26; doi: 10.1016/j.vaccine.2021.11.021. Epub 2021 Nov 26. PMID: 34844819.
Copy Download .nbib Format: NLM
Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical .

Antimicrobial agents and chemotherapy

Su H, Zhu M, Tsui CK, van der Lee H, Tehupeiory-Kooreman M, Zoll J, Engel T, Li L, Zhu J, Lu Z, Zhang Q, Verweij PE, Deng S.
PMID: 33685896
Antimicrob Agents Chemother. 2021 Mar 08; doi: 10.1128/AAC.02546-20. Epub 2021 Mar 08.

Triazole resistance in

Cite
Su H, Zhu M, Tsui CK, et al. Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical . Antimicrob Agents Chemother. 2021;doi: 10.1128/AAC.02546-20.
Su, H., Zhu, M., Tsui, C. K., van der Lee, H., Tehupeiory-Kooreman, M., Zoll, J., Engel, T., Li, L., Zhu, J., Lu, Z., Zhang, Q., Verweij, P. E., & Deng, S. (2021). Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical . Antimicrobial agents and chemotherapy, . https://doi.org/10.1128/AAC.02546-20
Su, Huilin, et al. "Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical ." Antimicrobial agents and chemotherapy vol. (2021). doi: https://doi.org/10.1128/AAC.02546-20
Su H, Zhu M, Tsui CK, van der Lee H, Tehupeiory-Kooreman M, Zoll J, Engel T, Li L, Zhu J, Lu Z, Zhang Q, Verweij PE, Deng S. Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical . Antimicrob Agents Chemother. 2021 Mar 08; doi: 10.1128/AAC.02546-20. Epub 2021 Mar 08. PMID: 33685896; PMCID: PMC8092882.
Copy Download .nbib Format: NLM
Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015.

European archives of psychiatry and clinical neuroscience

Glocker C, Grohmann R, Engel R, Seifert J, Bleich S, Stübner S, Toto S, Schüle C.
PMID: 33768297
Eur Arch Psychiatry Clin Neurosci. 2021 Dec;271(8):1425-1435. doi: 10.1007/s00406-021-01241-3. Epub 2021 Mar 25.

Galactorrhea is a well-known adverse drug reaction (ADR) of numerous antipsychotic drugs (APD) and is often distressing for those affected. Methodological problems in the existing literature make it difficult to determine the prevalence of symptomatic hyperprolactinemia in persons treated...

Cite
Glocker C, Grohmann R, Engel R, et al. Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015. Eur Arch Psychiatry Clin Neurosci. 2021;271(8):1425-1435doi: 10.1007/s00406-021-01241-3.
Glocker, C., Grohmann, R., Engel, R., Seifert, J., Bleich, S., Stübner, S., Toto, S., & Schüle, C. (2021). Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015. European archives of psychiatry and clinical neuroscience, 271(8), 1425-1435. https://doi.org/10.1007/s00406-021-01241-3
Glocker, C, et al. "Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015." European archives of psychiatry and clinical neuroscience vol. 271,8 (2021): 1425-1435. doi: https://doi.org/10.1007/s00406-021-01241-3
Glocker C, Grohmann R, Engel R, Seifert J, Bleich S, Stübner S, Toto S, Schüle C. Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015. Eur Arch Psychiatry Clin Neurosci. 2021 Dec;271(8):1425-1435. doi: 10.1007/s00406-021-01241-3. Epub 2021 Mar 25. PMID: 33768297; PMCID: PMC8563638.
Copy Download .nbib Format: NLM
Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.

EBioMedicine

Moncunill G, Aguilar R, Ribes M, Ortega N, Rubio R, Salmerón G, Molina MJ, Vidal M, Barrios D, Mitchell RA, Jiménez A, Castellana C, Hernández-Luis P, Rodó P, Méndez S, Llupià A, Puyol L, Rodrigo Melero N, Carolis C, Mayor A, Izquierdo L, Varela P, Trilla A, Vilella A, Barroso S, Angulo A, Engel P, Tortajada M, García-Basteiro AL, Dobaño C.
PMID: 35032961
EBioMedicine. 2022 Jan 11;75:103805. doi: 10.1016/j.ebiom.2021.103805. Epub 2022 Jan 11.

BACKGROUND: Two doses of mRNA vaccination have shown >94% efficacy at preventing COVID-19 mostly in naïve adults, but it is not clear if the second dose is needed to maximize effectiveness in those previously exposed to SARS-CoV-2 and what...

Cite
Moncunill G, Aguilar R, Ribes M, et al. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. EBioMedicine. 2022;75:103805doi: 10.1016/j.ebiom.2021.103805.
Moncunill, G., Aguilar, R., Ribes, M., Ortega, N., Rubio, R., Salmerón, G., Molina, M. J., Vidal, M., Barrios, D., Mitchell, R. A., Jiménez, A., Castellana, C., Hernández-Luis, P., Rodó, P., Méndez, S., Llupià, A., Puyol, L., Rodrigo Melero, N., Carolis, C., Mayor, A., Izquierdo, L., Varela, P., Trilla, A., Vilella, A., Barroso, S., Angulo, A., Engel, P., Tortajada, M., García-Basteiro, A. L., & Dobaño, C. (2022). Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. EBioMedicine, 75103805. https://doi.org/10.1016/j.ebiom.2021.103805
Moncunill, Gemma, et al. "Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers." EBioMedicine vol. 75 (2022): 103805. doi: https://doi.org/10.1016/j.ebiom.2021.103805
Moncunill G, Aguilar R, Ribes M, Ortega N, Rubio R, Salmerón G, Molina MJ, Vidal M, Barrios D, Mitchell RA, Jiménez A, Castellana C, Hernández-Luis P, Rodó P, Méndez S, Llupià A, Puyol L, Rodrigo Melero N, Carolis C, Mayor A, Izquierdo L, Varela P, Trilla A, Vilella A, Barroso S, Angulo A, Engel P, Tortajada M, García-Basteiro AL, Dobaño C. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. EBioMedicine. 2022 Jan 11;75:103805. doi: 10.1016/j.ebiom.2021.103805. Epub 2022 Jan 11. PMID: 35032961.
Copy Download .nbib Format: NLM
HIV self-testing with digital supports as the new paradigm: A systematic review of global evidence (2010-2021).

EClinicalMedicine

McGuire M, de Waal A, Karellis A, Janssen R, Engel N, Sampath R, Carmona S, Zwerling AA, Suarez MF, Pai NP.
PMID: 34430835
EClinicalMedicine. 2021 Aug 13;39:101059. doi: 10.1016/j.eclinm.2021.101059. eCollection 2021 Sep.

BACKGROUND: HIV self-testing (HIVST) is recommended by the WHO as an innovative strategy to reach UNAIDS targets to end HIV by 2030. HIVST with digital supports is defined as the use of digital interventions (e.g., website-based, social media, mobile...

Cite
McGuire M, de Waal A, Karellis A, et al. HIV self-testing with digital supports as the new paradigm: A systematic review of global evidence (2010-2021). EClinicalMedicine. 2021;39:101059doi: 10.1016/j.eclinm.2021.101059.
McGuire, M., de Waal, A., Karellis, A., Janssen, R., Engel, N., Sampath, R., Carmona, S., Zwerling, A. A., Suarez, M. F., & Pai, N. P. (2021). HIV self-testing with digital supports as the new paradigm: A systematic review of global evidence (2010-2021). EClinicalMedicine, 39101059. https://doi.org/10.1016/j.eclinm.2021.101059
McGuire, Madison, et al. "HIV self-testing with digital supports as the new paradigm: A systematic review of global evidence (2010-2021)." EClinicalMedicine vol. 39 (2021): 101059. doi: https://doi.org/10.1016/j.eclinm.2021.101059
McGuire M, de Waal A, Karellis A, Janssen R, Engel N, Sampath R, Carmona S, Zwerling AA, Suarez MF, Pai NP. HIV self-testing with digital supports as the new paradigm: A systematic review of global evidence (2010-2021). EClinicalMedicine. 2021 Aug 13;39:101059. doi: 10.1016/j.eclinm.2021.101059. eCollection 2021 Sep. PMID: 34430835; PMCID: PMC8367787.
Copy Download .nbib Format: NLM
Showing 1393 to 1398 of 1398 entries